ClinicalTrials.gg
Status unknownNCT05210595Updated Jan 27, 2022

Optimal Dosage of Ticagrelor in Korean Patients With AMI

A Phase 4 interventional study of Clopidogrel 75 mg and Ticagrelor 60mg in Acute Myocardial Infarction and Ticagrelor, sponsored by Dong-A University. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-27.

Sponsored by Dong-A University · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing clopidogrel in Myocardial Infarction — 1 open to participants now, 1 under way, none of them phase 3. Clopidogrel · Myocardial Infarction.

Planned enrollment
20th of 27
120 · median 335
Started
2022
the only one that year
Phase 4
18 of 27
1 open now
Registered
27th of 27
by date
Lead sponsor
1 of 27
Dong-A University

Among the 27 studies testing clopidogrel in Myocardial Infarction, this one is the 20th largest by planned enrollment, is the only one that started in 2022, is one of 18 in phase 4, and was the 27th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

1 of the 27 studies testing clopidogrel in Myocardial Infarction is open now. Recruiting first, the newest first:

About clopidogrel

Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing clopidogrel in Myocardial Infarction, or all of them as a file.
02

Study summary

East Asian patients will be required optimal dose of newer P2Y12 inhibitor (ticagrelor) to determine the safer treatment and better outcome. Whether low dose of ticagrelorI is more adequate for clinical practice in Korea is unclear. Therefore, the investigators aim to evaluate efficacy and safety of low dose of ticagrelor in Acute Myocardial Infarction (AMI) undergoing percutaneous coronary intervention(PCI).

Read the detailed description

In recent years, newer oral P2Y12 receptor blocker (ticagrelor) has been strong recommendations for management of patients with AMI undergoing (PCI). This drug provided more profound inhibitory effects than clopidogrel, which could lead to marked reduction in ischemic events, with relatively increase in bleeding complication, specific to low body weight, especially in women and East Asian patients.

03

Conditions studied

  • Acute Myocardial Infarction
  • Ticagrelor

Keywords

  • Ticagrelor
  • De-escalation Strategy
  • Korean
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients present with acute myocardial infarction undergoing PCI.
  • Patients receiving ticagrelor; Male or female gender; Age 20-75 years.
  • Patients provide written prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Low body weight (\<60kg).
  • History of hemorrhagic stroke.
  • History of upper gastrointestinal bleeding in recent 6 months.
  • Bleeding tendency.
  • Thrombocytopenia defined by \< 100,000/ml.
  • Anemia defined by \< 10 g/dl.
  • Renal dysfunction defined as serum creatinine > 2.5 mg/dl.
  • Severe hepatic dysfunction defined as serum transaminase > 3 times normal limit.
  • Known severe or bradycardia (sick sinus syndrome (SSS) or high degree AV block without pacemaker protection).
  • Current treatment with drugs interfering with metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromycin.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Control group

    Clopidogrel 75 mg/day as maintenance dose

    Drug: Clopidogrel 75 mg

  • Experimental
    Treatment group 1

    De-escalation strategy dose receive ticagrelor 60 mg twice daily

    Drug: Ticagrelor 60mg

  • Experimental
    Treatment group 2

    De-escalation strategy dose receive ticagrelor 45 mg twice daily

    Drug: Ticagrelor 45 mg

Interventions

  • DrugClopidogrelStudies of ClopidogrelClopidogrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    75 mg/day as maintenance dose.

    Also known as: Plavix 75 mg

  • DrugTicagrelorStudies of TicagrelorTicagrelor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.

    Also known as: Brilinta 60 mg

  • DrugTicagrelorStudies of TicagrelorTicagrelor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .

    Also known as: Brilinta 45 mg

06

What researchers measure

Primary outcomes

  1. Optimal platelet reactivity (OPR) rate

    OPR, indicate 85 to 208 for P2Y12 reaction units (PRU)

    Time frame: At 1 month

Secondary outcomes

  1. Major adverse cardiac and cerebrovascular events (MACCE)

    MACCE: composite of cardiac death, non-fatal myocardial infarction, target lesion / vessel revascularization and stroke

    Time frame: At 9 months

  2. Bleeding events

    BARC: Bleeding Academic Research Consortium (BARC ≥2).

    Time frame: At 9 months.

07

Study locations

1 of 1 sites recruiting
  • DongA University Hospital
    Busan, 602-715, Korea, Republic of
    Recruiting
    • Moo Hyun Kim, M.D. · Contactkimmh@dau.ac.kr · +82-51-240-2976
    • Moo Hyun Kim, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2022, 11 months after the start.

Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 11 months is below that.

Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2022
First posted
Jan 27, 2022
StartActual
Jan 1, 2022
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2023
Last update
Jan 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05210595
Lead sponsor
Dong-A University
Responsible party
Moo Hyun Kim (Professor, Dept. of Cardiology Dong-A University Hospital, Dong-A University) — Principal investigator
First posted
Jan 27, 2022
Start date
Jan 1, 2022
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Jan 27, 2022

Study contacts

Moo Hyun Kim, MD
Contact
kimmh@dau.ac.kr
+82-51-240-2976
Moo Hyun Kim, MD
principal investigator · Dong-A University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clopidogrel · Ticagrelor

Start the discussion